Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type
Status:
Recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The first Part: recruiting untreated ENKL patients with extensive stage I or limited stage II
disease (only referring to patients with the invasion of Waldeyer's ring and cervical lymph
nodes) . Patients are randomly divided into two arms, IPGDP regimen chemotherapy followed by
radiotherapy or radiotherapy followed by IPGDP regimen chemotherapy. IPGDP regimen for both
arms are 3 cycles. And the chemotherapy is repeated every 3 weeks..
The second part: recruiting extensive stage II ,stage III-IV, relapsed or refractory ENKL
patients. Patients receive 6 cycles of IPGDP regimen chemotherapy. And the chemotherapy is
repeated every 3 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborators:
307 Hospital of PLA First Hospital of China Medical University Guangdong General Hospital Guangdong Provincial People's Hospital Hebei Medical University Fourth Hospital Nanfang Hospital of Southern Medical University People's Hospital of Guangxi Qilu Hospital Qilu Hospital of Shandong University Shandong Cancer Hospital and Institute Shanxi Dayi Hospital Shanxi Province Cancer Hospital The Second Affiliated Hospital of Dalian Medical University Tianjin Medical University Cancer Institute and Hospital Xuzhou Medical University Zhangzhou Municipal Hospital of Fujian Province